

**Supplementary Table 4. Visual outcomes analyses for treatment specifics.**

T-test was performed for continuous data. Dose homogeneity defined as maximum dose to prescription dose ratio (MDPD), Total tumor dose, Max dose to optic nerve, lesion size (PTV, given that generally a 0 mm margin was used) were all assessed for impact on overall vision status (worsened vs improved/unchanged, as defined by WEVO criteria).

CATEGORY	OUTCOME	COUNT	MEAN (SD)	UNPAIRED T-TEST P VALUE
<b>MDPD</b>	Worsened	6	1.280 ± 0.05968	0.3922
	Improve/unchanged	20	1.221 ± 0.03244	
<b>Total tumor dose (Gy)</b>	Worsened	7	52.97 ± 0.6639	0.6236
	Improve/unchanged	22	52.61 ± 0.3539	
<b>Max dose to tumor (Gy)</b>	Worsened	6	64.53 ± 3.419	0.6573
	Improve/unchanged	19	62.99 ± 1.612	
<b>Max dose to optic nerve (Gy)</b>	Worsened	7	50.63 ± 7.458	0.4218
	Improve/unchanged	19	55.95 ± 2.893	
<b>Lesion size (cc)</b>	Worsened	7	1.071 ± 0.2309	0.0631
	Improve/unchanged	18	2.568 ± 0.4641	